Department of Endocrinology and Internal Medicine (MEA), Aarhus University Hospital, Aarhus, Denmark.
Eur J Intern Med. 2012 Apr;23(3):278-82. doi: 10.1016/j.ejim.2011.10.013. Epub 2011 Nov 15.
Data on mortality associated with Cushing's disease (CD) and Cushing's syndrome (CS) are scarce.
To perform a systematic review and meta-analysis of mortality studies in patients with CD and CS secondary to a benign adrenal adenoma.
A search was performed in seven electronic databases. Sixty-six articles were retrieved for analysis and 7 included in the final study. The main outcome measure was standardized mortality ratio (SMR).
STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: Studies reporting SMR for patients diagnosed with CD and/or CS. Outcomes were stratified by subtype of Cushing's syndrome.
Studies were appraised by two authors and were synthesized using a weighted estimate based on the standard error of the SMR.
The weighted mean of SMR for patients with CD was 1.84 (95% confidence interval (CI): 1.28-2.65). CD patients with persistent disease after initial surgery had a SMR of 3.73 (95% CI: 2.31-6.01), whereas mortality of CD patients with initial remission did not differ significantly from the general population (SMR: 1.23 (95% CI: 0.51-2.97)). SMR for patients with a benign adrenal adenoma was 1.90 (95% CI: 0.93-3.91). Age, sex and observation time did not significantly impact mortality.
CD as opposed to CS due to a benign adrenal adenoma is associated with an excess mortality, which is attributed to patients in whom initial surgical cure is not obtained. This underlines the importance of a rigorous and early follow-up of newly operated patients with CD.
关于库欣病(CD)和库欣综合征(CS)患者死亡率的数据很少。
对继发于良性肾上腺腺瘤的 CD 和 CS 患者死亡率进行系统回顾和荟萃分析。
在七个电子数据库中进行了搜索。检索了 66 篇文章进行分析,其中 7 篇纳入最终研究。主要观察指标为标准化死亡率比(SMR)。
研究入选标准、参与者和干预措施:报告诊断为 CD 和/或 CS 患者 SMR 的研究。结果按库欣综合征的亚型进行分层。
两名作者对研究进行评估,并使用基于 SMR 标准误差的加权估计值进行综合。
CD 患者的加权平均 SMR 为 1.84(95%置信区间[CI]:1.28-2.65)。初次手术后疾病持续的 CD 患者 SMR 为 3.73(95% CI:2.31-6.01),而初始缓解的 CD 患者死亡率与一般人群无显著差异(SMR:1.23(95% CI:0.51-2.97))。继发于良性肾上腺腺瘤的 CS 患者 SMR 为 1.90(95% CI:0.93-3.91)。年龄、性别和观察时间对死亡率无显著影响。
与继发于良性肾上腺腺瘤的 CS 相比,CD 患者的死亡率过高,这归因于初始手术治疗未获得痊愈的患者。这突显了对新手术治疗的 CD 患者进行严格和早期随访的重要性。